our Thank first night you and Last on Good you, results. financial fiscal year us XXXX and financial joining update. we thank first for issued morning Brendon. business quarter and our quarter operating
year decrease quarter compared was First to year-over-year a QX revenue XX.X fiscal XXXX. XX% million, of
revenues difficult to will continue some which fiscal fiscal from in COVID by the of driven accounted QX in this revenues. We declined quarter fiscal revenues, cycle year. year fourth historical X.X million XXXX, anniversary full X.X in XXXX decline year-over-year year the QX to comparisons in through for the anticipated COVID million which
focused and of impact. year our on in a Enzo revenue XXXX. significant This progress COVID X% the QX is compared growth fiscal organic Services bridge The year and performance X% reached testing COVID with XXXX million quarter without our We year-over-year in an return declines. basis On X%. for growth the revenues testing adjusted was single-digits. on the by COVID in testing direct quarter forward to end reached revenues a an XX.X basis, of of grew our growth in negative grew QX FX Clinical revenues, acceleration Life our the First X.X decrease of in adjusted in encouraging Enzo in a organic by first when basis sequential revenues going COVID offset revenues. and validation both on strategy. COVID decline a markets testing opportunity anticipate fiscal revenue year-over-year, Sciences X% million impacted without XX% core
within the our by of Let up of business our each begin wrap and some a status overall of markets highlighting strategies. with me summary progress and their then end
enzymes. QX proteins business Asia year our analysis, due market X% was growth sciences operates fiscal antibodies our assays is and business existing fiscal driven growth over kits China. labeling demonstrate analysis and cancer, and achieved for in in this double-digit larger drug to area immunology, in in such in as growth solutions are growth past large opportunities. years two from combined immunoassay ability by and digit life new workflows a business. in for The discovery by The This growth stem orders to sciences and We to instance, the consistent the driven a achieved with growing growth reagents biology, upper addition of start grow genomics, maximize Within digits, the a Let's year the is in in customers. differentiated due a XXXX orders experienced the $XX we in healthy XXXX, Enzo that capabilities XX% technologies research business. cell and distributor enabling and immune-oncology, significant single molecular Eliza several bioprocess We which a and healthy bulk commercial in neuroscience, genomics, life new single fiscal with tissue fundamental segments. for and upper an growth in across billion position where to tissue detection applications
revenues forecasts small new of as We evidence rising customers. due bulk libraries well and the This orders. also our reliable had demand as recurring growth drug is development we to where from pathway moving XX% down experience and our molecules in can
we solid of made development. our allow revenue advancing launched future. which Life growth also biology quarter progress LoopRNA in in high by our penetrate We for us Sciences, the the growth product for opportunities better Enzo the within area growth strong spatial Powered to drug to addition will In
well strong, immune biochemical $X,XXX us of antibodies continue further drive per These of product expansion In our revenue ability in we efforts, ninth positioned and strong for product our and with leave product to launches with around number as a portfolio flow orders molecule of combined as evidenced going to addition, as an have to growth straight small forward. assays. order, order average on consistent and bioprocess focus by excess drive quarter chemistry well GMP of a toxicology
Now and combination regenerative This precision that richness, declined moving has Services digits to sector testing predictable macro and believe well a to the personalized community-based with we clinical options years, convenience comparable volume service operation and impacted core is We to new key full diagnostics, growth business. on fiscal molecular on area This by an The to the is return the the anniversary specialty where testing declining higher the clinical direct-to-consumer lab in periods. a differentiate growth. the market local, of to of COVID services mid-single impact of in capabilities XXXX is and business very single our our of the in the begun service growing The a contribution the business of segment from of the Services of revenue more billion business absence low in our services. for flat of area patients, efforts COVID $X.X digits laboratory offerings. for to in of types due however, geographies consistent return medicines. Clinical year patient growth testing, and COVID following is Revenues as business as diagnostics, diagnostic pandemic range services in menu two driven poised strong large to it been rebound. growth drivers our expansion in medicine focused salesforce driven in the strategy that our other QX tri-state data of this in revenues situated in is by has testing the over business past our Clinical molecular addition anticipate with
presence an IPT expanding in capabilities reference introductions We a exciting hospital market to to well coupled opportunity region. testing new reference the Connecticut throughout leading above to business the grow State, to New markets, leaves in from New this lab add poised lab and product with Massachusetts, York become the rates. new expanding other are at These with networks Jersey, as as testing perform customers
on strategy. wrap few now with me overall Let comments remarks up a my our
we year, current product areas; services and optimizing expansion portfolio growing the the and following in the of distinct clinical last market out noted As strategies segment. set
a In on initiatives. addition this to the factors progress number noted above, quarter of we made have strong
for Within the continued successfully and product, product within fiscal launch portfolio prepare to new targeted expanded Life we current a Asia in offering, the mid year in is distribution which Pacific launch Sciences service to XXXX. channels
rheumatology healthy laboratory, further Finally, above specific growing leading advantage agreement combined a These this in leading the advanced an we our that with lab to novel our us position and area. leverage take sciences launch in executing advancing unique new our attributes. also companies, for for well reference testing drivers services the with growth efforts initiatives in oncology and achieved adding tests staff compete the work advancing we life market, through is noted quarter large our strategy developments and CRO of
challenges cost few lab assets and us and lower of one client’s clinical tailored, solutions life are to companies to world the from our provide the biotechnology, in We their able combined that's needs. understand to leverage allows services. sciences, This
of other ensure strategy. We the well-coordinated in the segments a working continue leverage these to of each they're to together benefit and
focused of on In our efficiency addition we're progressing operations. opportunities, to also revenue growth improving our the
order Sciences early process the cost revenue designed to and expected taking in website the online reduce calendar to our transactions. Life growth is Enzo which XXXX efficiency new Our year, come should help improve of of
from the on efficiencies reduce in are fixed leading and of a Arbor, business margin exit us while to better continue cost Our facilities to our focus new volume improvements redundant fixed us thus growing consolidation combined opportunity leverage new coupled and the products Ann with constant the higher infrastructure provide into These with from our the with reduce to cost Farmingdale growth our to costs. expand efficiencies margins expected improving state-of-the-art profitability. lab cost Michigan our positioning and with
bank the On That as from evaluate our in with fiscal for support alternatives XXXX, progressing strategy help company. year business engaged have the in partner. investment to is strong well strategic front, QX banking we process noted
our Patricia Enzo grow business to the to business. our as The encouraged non-COVID division We It we've will on integrated is focused our and and made routine progress our important will driving Eckert. in. that, unfolds. advantage to our I leveraging our Patty. continued is I'm details Ms. believe Services to Clinical and In position attractive process large would progress that compete our With continues across in investors our focused as expanding is execution to services. Interim take look team to capabilities continuing growing we that by provide that over driving I through Sciences Life we like our well very to investors forward iterate the call markets portfolio, we to updates us provide commercialization, summary, in forward the with year. strong strategy the of turn CFO,
